Dolutegravir / lamivudine for the treatment of Human Immunodeficiency Virus (HIV-1) infected adults and adolescents over 12 years of age

Dolutegravir/lamivudine for the treatment of HIV infected adults and adolescents >12 years of age is recommended to be available as a treatment option through routine commissioning within the criteria set out in this document.

NHS England